Search results
Drug targeting clear cell renal cell carcinoma shows promising approach
Newswise· 18 hours agoApril 23, 2024 – In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center,...
Signs and Symptoms of Kidney Cancer
Health via Yahoo News· 5 days agoIn fact, kidney cancer is often found accidentally during a routine physical or imaging exam, such as an X-ray or MRI. There are three main types of kidney cancers: renal ...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 4 days agoPatients will receive Keytruda or Keytruda plus the vaccine after bladder or kidney removal. Bladder...
New trial shows immunotherapy post-surgery improves overall survival for kidney cancer
Medical Xpress· 6 days agoTreatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 1 day agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...
Strs Ohio Raises Holdings in Exelixis, Inc. (NASDAQ:EXEL)
ETF DAILY NEWS· 4 days agoStrs Ohio raised its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 9.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned ...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 1 day agoKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its ...
Analysts Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $251.70
ETF DAILY NEWS· 2 days agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports ...
BeiGene (NASDAQ:BGNE) Trading Down 2.4%
ETF DAILY NEWS· 3 days agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report)’s stock price dropped 2.4% during trading on Friday . The company traded as low as $126.97 and last traded at $128.77. Approximately 17,319 shares ...
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $52.65
ETF DAILY NEWS· 7 days agoJanux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) shares gapped down before the market opened on Monday . The stock had previously closed at $52.65, but opened at $51.05. Janux Therapeutics ...
